CyberKnife-based prostate cancer patient radioablation - early results of irradiation in 200 patients.

INTRODUCTION - Prostrate cancer (PC) is one of the most common malignancies and is frequently treated with an 8-week course of radiotherapy. CyberKnife (CK) based radioablation enables completion of therapy within 5-9 days.

The aim of this study is an evaluation of the effectiveness and tolerance of CyberKnife-based radioablation in prostate cancer patients.

MATERIALS AND METHODS - 200 PC patients (94 low risk [LR], 106 intermediate risk [IR]) underwent CK irradiation every other day (fraction dose [fd] 7. 25 Gy, total dose [TD] 36. 25 Gy, time 9 days). PSA varied from 1. 1 to 19. 5 (median 7. 7) and T stage from T1c to T2c. The percentage of patients with Androgen Deprivation Therapy (ADT), GI (gastrointestinal) and GU (genitourinary) toxicity (EORTC/RTOG scale), and PSA were checked at 1, 4 and 8 months, and thereafter every 6 months - up to a total of 26 months - post-treatment.

RESULTS - The percentage of patients without ADT increased from 47. 5% to 94. 1% after 26 months. The maximum percentage of acute G3 adverse effects was 0. 6% for GI, 1% for GU and G2 - 2. 1% for GI and 8. 5% for GU. No late G3 toxicity was observed. The maximum percentage of late G2 toxicity was 0. 7% for GI and 3. 4% for GU. Median PSA decreased from 7. 7 to 0. 1 ng/ml during FU. One patient relapsed and was treated with salvage brachytherapy.

CONCLUSIONS - We conclude that CK-based radioablation in low and intermediate risk PC patients is an effective treatment modality enabling OTT reduction and presents a very low percentage of adverse effects.

Central European journal of urology. 2015 Oct 15 [Epub]

Leszek Miszczyk, Aleksandra Napieralska, Agnieszka Namysł-Kaletka, Grzegorz Głowacki, Kinga Grabińska, Grzegorz Woźniak, Małgorzata Stąpór-Fudzińska

M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland. , M. Skłodowska-Curie Cancer Center and Institute of Oncology, Gliwice Branch, Poland.

PubMed